Each particle has its own charge and its own mass.
One in 12 children globally faces online sexual abuse: Lancet study Approximately one in 12 children worldwide experienced online sexual abuse in the past year, according to a study published in ...
At ESMO 2024, Lantheus will present additional clinical data from the Phase 3 SPLASH trial on 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer ...
SPLASH highlighted 177Lu-PNT2002 as a promising radioligand therapy option for chemotherapy-naïve mCRPC. The Phase III EORTC-1333-GUCG/PEACE III Trial in Asymptomatic or Mildly Symptomatic CRPC ...
Similarly, Point has a treatment that was going through phase 3 trials at the time of the arrangement, as the company investigated PNT2002 for the treatment of metastatic-castration resistant ...
Just a few months ago, Lilly snapped up POINT Biopharma for around $1.4 billion, adding a PSMA-targeted radioligand therapy called PNT2002, which is in the phase 3 SPLASH trial in patients with ...
After hours: 7:58:55 pm GMT-5 ...